Literature DB >> 10629563

Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2.

D Ribatti1, A Gualandris, M Belleri, L Massardi, B Nico, M Rusnati, P Dell'Era, A Vacca, L Roncali, M Presta.   

Abstract

A close relationship exists between angiogenesis and the formation of vascular lesions. The development of the vascular system in the chick embryo chorioallantoic membrane (CAM) may thus represent a model to study the effects of the deregulation of endothelial cell behaviour. Alterations of the developing vascular tree of the CAM were observed after exposure to murine aortic endothelial (MAE) cells overexpressing human fibroblast growth factor-2 (FGF2) cDNA (pZipFGF2 MAE cells), or to their conditioned medium (CM). pZipFGF2 MAE cells injected into the allantoic sac or applied on to the CAM of day 8-9 chick embryos induce neovascularization and the appearance of haemangioma-like lesions. This activity was not prevented by anti-FGF2 antibodies. The CM from pZipFGF2 MAE cells was also active when adsorbed into a gelatin sponge and applied on to the CAM, both in the absence and in the presence of anti-FGF2 antibodies. No effects on vessel development were exerted by parental MAE cells, FGF2-transfected NIH 3T3 fibroblasts, or their conditioned media. In vitro, pZipFGF2 MAE cell CM caused parental MAE cells to invade fibrin gels and to undergo morphogenesis on Matrigel. This activity was not mimicked by recombinant FGF2 nor affected by anti-FGF2 antibodies, and depended on a M (r) approximately 45 000 heat-labile heparin-binding factor. Size exclusion chromatography of pZipFGF2 MAE cell CM demonstrated that the in vitro activity co-purified with an in vivo angiogenic capacity. Thus, FGF2 overexpression in mouse endothelial cells induces the production of an angiogenic activity distinct from FGF2, which may contribute to the genesis of angioproliferative lesions. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629563     DOI: 10.1002/(SICI)1096-9896(199912)189:4<590::AID-PATH461>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Angiostatin effects on endothelial cells mediated by ceramide and RhoA.

Authors:  N Gupta; E Nodzenski; N N Khodarev; J Yu; L Khorasani; M A Beckett; D W Kufe; R R Weichselbaum
Journal:  EMBO Rep       Date:  2001-06       Impact factor: 8.807

2.  Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor.

Authors:  Sonya B Seif-Naraghi; Dinah Horn; Pamela J Schup-Magoffin; Karen L Christman
Journal:  Acta Biomater       Date:  2012-06-28       Impact factor: 8.947

3.  The CAM Assay as an Alternative In Vivo Model for Drug Testing.

Authors:  Regine Schneider-Stock; Domenico Ribatti
Journal:  Handb Exp Pharmacol       Date:  2021

4.  In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane.

Authors:  Domenico Ribatti; Giuseppe De Falco; Beatrice Nico; Roberto Ria; Enrico Crivellato; Angelo Vacca
Journal:  J Anat       Date:  2003-09       Impact factor: 2.610

5.  Dramatic resolution of vitreous hemorrhage after an intravitreal injection of dobesilate.

Authors:  Pedro Cuevas; Luis Antonio Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Mil Med Res       Date:  2015-09-08

Review 6.  Application of the chick embryo chorioallantoic membrane in neurosurgery disease.

Authors:  Yong-Jie Yuan; Kan Xu; Wei Wu; Qi Luo; Jin-Lu Yu
Journal:  Int J Med Sci       Date:  2014-10-27       Impact factor: 3.738

7.  Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.

Authors:  Daria Leali; Roberta Bianchi; Antonella Bugatti; Stefania Nicoli; Stefania Mitola; Laura Ragona; Simona Tomaselli; Grazia Gallo; Sergio Catello; Vincenzo Rivieccio; Lucia Zetta; Marco Presta
Journal:  J Cell Mol Med       Date:  2010-07-20       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.